CEA、CA125和CA199在结直肠癌患者贝伐单抗治疗效果评估中的应用  

Application of carcinoembryonic antigen,carbohydrate antigen 125 and carbohydrate antigen 199 in evaluating the therapeutic effect of bevacizumab on colorectal cancer

作　　者：王毅 赵红梅 郭鹏伟 郑波 崔海涛 WANG Yi;ZHAO Hongmei;GUO Pengwei(Department of General Surgery,Zhangjiakou First Hospital,Hebei,Zhangjiakou 075000,China;不详)

机构地区：[1]河北省张家口市第一医院普通外科,075000 [2]河北省张家口市第五医院检验科

出　　处：《河北医药》2023年第17期2632-2635,共4页Hebei Medical Journal

基　　金：河北省医学科学研究课题计划(编号:20221886)。

摘　　要：目的探究癌胚抗原(CEA)、糖链抗原125(CA125)、糖链抗原199(CA199)在结直肠癌患者贝伐单抗治疗效果评估中的应用及对患者预后的预测价值。方法选取2021年3月至2022年3月接受治疗的晚期结直肠癌患者100例及结直肠良性病变患者50例,晚期结直肠癌患者均使用贝伐单抗治疗。酶联免疫吸附试验法检测血清CEA、CA125、CA199水平,评估结直肠癌患者贝伐单抗治疗效果,对比不同研究对象血清CEA、CA125、CA199水平,对比不同病理特征患者CEA、CA125、CA199水平,对比贝伐单抗治疗前后及不同疗效结直肠癌患者CEA、CA125、CA199水平,分析CEA、CA125、CA199对结直肠癌患者预后的预测价值。结果结直肠癌患者血清CEA、CA125、CA199水平均高于结直肠良性病变患者(P<0.05)。与肿瘤直径≤5 cm、无腹腔淋巴结转移、Ⅲ期结直肠癌患者相比,肿瘤直径>5 cm、有腹腔淋巴结转移、Ⅳ期结直肠癌患者血清CEA、CA125、CA199水平较高(P<0.05)。与治疗前比较,结直肠癌患者使用贝伐单抗治疗后血清CEA、CA125、CA199水平降低(P<0.05)。与治疗无效患者相比,治疗有效患者血清CEA、CA125、CA199水平较低(P<0.05)。与CEA、CA125、CA199单项检测相比,联合检测对结直肠癌患者预后的预测价值较高(P<0.05)。结论结直肠癌患者血清CEA、CA125、CA199水平明显较高,且三者水平变化与患者病理特征、贝伐单抗治疗效果具有一定相关性,联合检测CEA、CA125、CA199水平对使用贝伐单抗治疗的结直肠癌患者预后具有较高的预测价值。Objective To explore the application of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199)in evaluating the therapeutic effect of bevacizumab on colorectal cancer and their prognostic value.Methods A total of 100 patients with advanced colorectal cancer and 50 patients with benign colorectal disease treated in our hospital from March 2021 to March 2022 were enrolled.All patients with advanced colorectal cancer were treated with bevacizumab.Enzyme-linked immunosorbent assay(ELISA)was used to detect serum levels of CEA,CA125 and CA199.The therapeutic effect of bevacizumab on colorectal cancer was evaluated.Serum levels of CEA,CA125 and CA199 in patients with advanced colorectal cancer versus those with benign colorectal disease,and before vs after bevacizumab treatment were compared.The predictive value of CEA,CA125 and CA199 for the prognosis of colorectal cancer was analyzed.Results Serum levels of CEA,CA125 and CA199 in patients with colorectal cancer were significantly higher than those with benign colorectal disease(P<0.05).Compared with patients with advanced colorectal cancer presenting tumor diameter≤5cm,no abdominal lymph node metastasis and stageⅢ,those with tumor diameter>5cm,abdominal lymph node metastasis and stageⅣhad significantly higher levels of CEA,CA125 and CA199(P<0.05).Compared with those before treatment,serum levels of CEA,CA125 and CA199 were significantly lower in advanced colorectal cancer patients treated with bevacizumab(P<0.05).Serum levels of CEA,CA125 and CA199 in effectively treated patients with advanced colorectal cancer were significantly lower than those with ineffective treatment(P<0.05).Compared with a single detection of serum CEA,CA125 and CA199,a combination detection had a higher prognostic value for colorectal cancer(P<0.05).Conclusion Serum levels of CEA,CA125 and CA199 significantly increase in patients with colorectal cancer,and their changes are correlated with the pathological characteristics and the treatment effect

关 键 词：结直肠癌 贝伐单抗 癌胚抗原 糖链抗原125 糖链抗原199 

分 类 号：R735.37[医药卫生—肿瘤]